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Abstract
Background: Endometriosis is a chronic gynecological disease resulting from complex 
interactions between genetic, hormonal, environmental and oxidative stress and intrinsic 
inflammatory components. The aim of this study was to investigate the potential asso-
ciation of the 763C>G polymorphism in the secretory phospholipase A2 group IIa gene 
(PLA2G2A) with the risk of endometriosis in Iranian women.    
Materials and Methods: Ninety seven patients with endometriosis along with 107 wom-
en who were negative for endometriosis after laparoscopy and laparatomy, and served as 
the control group, were enrolled for this cross-sectional study. Samples were genotyped 
using the polymerase chain reaction-restriction fragment length polymorphism method. 
Results: Multivariate analysis was used to examine the association between the risk of en-
dometriosis and the 763C>G polymorphism of PLA2G2A. Genotype distributions of PLA-
2G2A were significantly different between patients and the controls (p<0.001, OR=0.22, 95% 
CI=0.21-0.39). Correlation analysis showed that there was a significant association between 
the normal homozygous genotype and susceptibility to endometriosis (p<0.001). 
Conclusion: The present study suggests that the 763C>G polymorphism of PLA2G2A plays 
an important role as an independent factor in the risk of endometriosis in Iranian women.     
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Introduction 
Endometriosis is one of the most frequent dis-
orders in gynecology that is characterized by de-
velopment of endometrial tissue outside the uterus 
(1). Endometriosis affects >10% of all women of 
reproductive age and >30% of all infertile women 
(2, 3). The common symptoms of endometriosis 
are pelvic pain, dysmenorrhoea, dyspareunia and 
infertility (4). The disease is diagnosed by laparos-
copy with or without biopsy for histological diag-
nosis (4, 5). According to extent, endometriosis 
is classified as stage I (minimal), stage II (mild), 
stage III (moderate) and stage IV (severe) (6). 
Previous studies have demonstrated that oxida-
tive stress and inflammatory activity as well as 
genetic abnormalities may be associated with 
the development and progression of endome-
triosis (2, 7, 8).
 Similar to the process that exists in cardiovascular 
disease, an abnormal lipid profile including increased 
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low-density lipoprotein (LDL) , decreased high den-
sity lipoprotein (HDL) and subsequently de-
creased HDL and, production of oxidized LDL 
(oxLDL) particles in peritoneal fluid ,could be 
involved in the development of endometriosis 
(9, 10). Melo et al showed that the abnormal 
lipid profile with elevated LDL and Non-HDL 
may increase oxidative stress and inflammation 
in the peritoneal fluid of women and subse-
quently the risk of endometriosis (11). Secre-
tory phospholipase A2 group IIa (sPLA2IIa) is a 
superfamily of enzymes that hydrolyse the sn-2 
ester bond  of glycerophospholipids to produce 
non-esterified free fatty acids (NEFAs) and 
lysophospholipids (12).
Release of NEFA arachidonic acid (AA) is 
a key step as a precursor in the production of 
eicosanoids such as leukotrines, thromboxanes 
and prostaglandin E2 (13). This process there-
fore promotes the production of pro-inflam-
matory lipid mediators which aid the initiation 
and maintenance of prolonged inflammatory re-
sponses in the body (14, 15). Also studies have 
shown that overexpression of human sPLA2I-
Ia results in increased lesion size and oxida-
tive stress (16, 17). The human sPLA2IIa gene 
(PLA2G2A) is located on chromosome 1p34-
36. Several single nucleotide polymorphisms 
(SNP) previously identified, capture 92% of the 
variation of PLA2G2A (18).
 The 763C>G polymorphism (rs11573156), in 
the 5´UTR which lies in exon 2 of  PLA2G2A , 
showed strong association with sPLA2IIa levels 
and coronary artery disease (CAD) risk (19-21). 
Several studies have found association between 
sPLA2IIa gene polymorphisms and CAD risk 
(18, 22, 23) but no study has been conducted 
on endometriosis. The aim of this study was to 
determine the prevalence of the 763C>G poly-
morphism of PLA2G2A in women with endo-
metriosis with respect to the control group and 
its relationship with the risk of endometriosis in 
the Iranian population.
Materials and Methods
Subjects
Women with chronic pelvic pain or infertil-
ity referred to the Kosar Hospital in Qazvin, 
Iran for diagnostic laparoscopy between April 
2011 and April 2012 were recruited for this 
cross-sectional study.  Among 310 women, 204 
were eligible and consented to participate in the 
study. Endometriosis patients and the control 
group were aged between 18 and 42. To obtain 
a more homogeneous population and verify that 
no endometriosis is present, controls were also 
selected from women undergoing laparoscopy. 
A total of 97 patients had surgical and histo-
logical evidence of endometriosis, while 107 
patients without the disease served as controls 
(women with uterine myoma, dermoid cyst, 
paraovarian cyst, serous cyst and healthy wom-
en). Endometriosis was confirmed by diagnos-
tic laparoscopy or laparotomy in both groups. 
In the endometriosis group, stage of the disease 
was diagnosed according to the revised Ameri-
can Fertility Society Classification (6).
Among the endometriosis patients, patients 
were diagnosed with stage I, 13 patients with 
stage II, 35 patients with stage III 10 and 39 
patients with stage IV. None of the patients had 
received hormone therapy during the previous 
year. Women who had received anti-inflamma-
tory drugs and contraceptives in the past three 
months, or had urological disease, endocrine 
disorders, familial dyslipidemia and chronic in-
flammatory were not included in the study. The 
study was approved by the ethics committee of 
Qazvin University of Medical Sciences.
Assay of plasma lipid 
Plasma total cholesterol (TC), High density li-
poprotein-cholesterol (HDL-C) and triglyceride 
(TG) were assed using enzymatic method. (Selec-
tra XL-VITA lab. Holland). Low-density lipopro-
tein- cholesterol (LDL-C) was calculated using the 
Friedewald equation: (LDL-C=total cholesterol 
(TC) - (HDLC) + TG/5) (24). All samples were 
stored at -70˚C for later simultaneous measuret-
ments.
Genomic DNA analysis
Genomic DNA was extracted from the leuko-
cytes of blood samples using the Qiagen DNA pu-
rification kit (Qiagen, USA). An 86 bp sequence 
of the sPLA2IIa gene was amplified by polymer-
ase chain reaction (PCR) in a DNA thermal cycler 
(ABI, Veriti, USA) using oligonucleotide primers 
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F: 5´- CAGCCTTGTGCCTCACCTA -3´ and R: 
5´ CAGGCCGTCTTGTTTGTTCTG -3´.
The PCR conditions were 94˚C for 5 minutes, 
35˚C cycles of 94˚C for 45 seconds, 55˚C for 
1 minute,72˚C for 1 minute, followed by 72˚C 
for 7 minutes (18). TseI enzyme (New Eng-
land Biolabs, Inc., Beverly, MA) was used as 
a restriction enzyme. Samples were electro-
phoresed in polyacrylamide gel and the gel was 
then visualized by standard staining method 
(Fig 1). Expected fragment size combinations 
were 86 bp band (rare homozygotes), 86/46/40 
bp ( heterozygotes) and 46/40 bp (common ho-
mozygotes).
Fig 1: The ischemic picture sPLA2IIa gene of the amplicon, the position of the 763C>G polymorphism, the place of the restric-
tion enzyme with its recognition site as well as the location of primers.
Gel picture analysis with the restriction enzyme TseI of  PLA2G2A 763C>G genotypes in genomic DNA of the study subjects. 
Lane M: molecular weight marker 50 bp; lanes 10 and 13:homozygous GG; lanes 3, 4, 8, 9, 12: heterozygous CG: lanes 1, 2, 5, 
6, 7, 11: homozygous wild-type CC.
Int J Fertil Steril, Vol 8, No 4, Jan-Mar 2015               440
Sahmani et al.
Statistical analysis 
Values were presented as mean ± SD, and statisti-
cal significance was defined as p values less than 0.05 
(p≤0.05). Statistically significant differences in mean 
between genotypes were assessed by t test. Multivar-
iate analysis was used to compare variable param-
eters between groups. Logistic regression analyses 
were performed for evaluating genotype distribution 
with respect to the presence of endometriosis as a 
dependent variable. All analyses were carried out us-
ing the statistical package for social sciences version 
11.0 (SPSS, Chicago, IL, USA).
Results
Demographic and metabolic parameters of pa-
tients and controls are shown in table 1. The mean 
of age for the endometriosis and control groups 
were 29.8 ± 5.4 and 29.5 ± 5.5 years respectively, 
(p=0.66). The body mass index (BMI) of the en-
dometriosis group (25.1 ± 3.3 kg/m2) was signifi-
cantly different from the control group (26.9 ± 3.9 
kg/m2) (p=0.001), while for, waist circumference 
there was no such difference (endometriosis: 80.6 
± 9.1 cm vs. control: 81.2 ± 9.7 cm, p=0.69). The 
total cholesterol (TC) and LDL levels of the endo-
metriosis group was significantly higher than the 
control group (p<0.001). Similarly, HDL levels 
were higher in the endometriosis group (46±10 
mg/dL vs. 40 ± 9 mg/dL, p<0.001). TG levels were 
higher in the endometriosis group but was not sig-
nificantly different between the two groups (128 ± 
48 mg/dL vs. 127 ± 47 mg/dL, p=0.86).The geno-
type distributions of both groups were in Hardy-
Weinberg equilibrium (p>0.05). Chi-square analy-
sis between genetic groups identified that normal 
genotypes have more susceptibility than those car-
rying rare alleles (p<0.001).
The distribution of genotypes was different 
between the endometriosis group and the con-
trol group (68.4% CC, 29.5% CG, 2.1% GG vs. 
31.8%, 51.4%, 16.8% respectively, p<0.001) (Ta-
ble 2). By logistic regression analysis, the risk 
of endometriosis in different genetic groups was 
calculated (Table 3). The analysis showed that in 
the normal allele homozygous genotype, the risk 
of endometriosis was more than the other groups. 
Moreover, the analysis, after adjustment for fac-
tors such as BMI, HDL-C and LDL-C, the risk of 
endometriosis in patients with normal homozy-
gous genotype was more than in those with the 
rare allele (p<0.001,OR=0.30,95% CI=0.14-0.63). 
Analysis of variance showed that in women with 
endometriosis, there is an increase in total  TC and 
LDL-C compared with the control group (p<0.001, 
Table 4).
Table 1: Demographic and metabolic parameters of patients with endometriosis and the control group
PEndometriosis (n=95)Control (n=107)
0.6629.8 ± 5.429.5 ± 5.5Age (Y)
0.00125.1 ± 3.326.9 ± 3.9Body mass index (kg/m2)
0.6980.6 ± 9.181.2 ± 9.7Waist (cm)
<0.001216 ± 38175 ± 30Cholesterol (mg/dl)
0.86128 ± 48127 ± 47Triglyceride (mg/dl)
<0.00146 ± 1040 ± 9HDL-C (mg/dl)
<0.001130 ± 22101 ± 20 LDL-C (mg/dl)
Values are mean ± standard deviation.
HDL-C; High density lipoprotein-cholesterol and LDL-C; Low-density lipoprotein-cholesterol. 
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Table 2: Genotype distributions in patients with endometriosis versus control
PEndometriosis (n=95)Control (n=107)Gene
PLA2G2A (%)
65 (68.4%)34 (31.8%)CC
28 (29.5%)55 (51.4%)CG
2 (2.1%)18 (16.8%)GG
P value: Chi-square test. CC; Common homozygotes, CG; Heterozygotes  and GG; Rare homozygotes.
Table 3: Logistic regression analysis of individual alleles with respect to the presence of endometriosis
Multivariate*Univariate
P95% CIORP95% CIOR
0.0010.14-0.630.30<0.0010.12-0.390.22PLA2G2A
Values are 95% confidence intervals (95%CI) of the odds ratios (OR).
*Adjusted for body mass index (BMI), HDL-C and LDL-C.
Table 4: Metabolic parameters according to genotypes
PLA2G2A
PGGCGCC
208399N
0.5530.7 ± 5.529.3 ± 4.629.8 ± 5.5Age (Y)
0.1926.4 ± 4.826.5 ± 4.025.5 ± 3.2Body mass index( kg/m2)
0.1978.0 ± 9.880.5 ± 10.281.9 ± 8.5Waist (cm)
<0.001173 ± 29186 ± 38206 ± 40Cholesterol (mg/dl)
0.52125 ± 45124 ± 42131 ± 52Triglyceride (mg/dl)
0.1942 ± 942 ± 1044 ± 9 HDL-C (mg/dl)
<0.001101 ± 21109 ± 25121 ± 25LDL-C (mg/dl)
Values are means ± SD, P values obtained by ANOVA.
HDL-C; High density lipoprotein-cholesterol, LDL-C; Low-density lipoprotein- cholesterol, CC; Common homozygotes, CG; 
Heterozygotes and GG; Rare homozygotes.
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Discussion
The atherogenic lipids have a potent activity 
to induce endothelium dysfunction and lesion 
formation (25-27). Secretory PLA2IIa enhances 
LDL oxidation and promotes the formation of 
bioactive phospholipids via the release of poly-
unsaturated free fatty acids. This can be a cause 
in stimulating monocyte-endothelium interac-
tion (28). Secretory PLA2IIa and oxLDL are 
involved in inflammation and oxidative stress 
and are accepted as oxidative and inflammato-
ry markers (29). Immunohistochemistry (IHC) 
with anti-human PLA2IIa demonstrated that 
sPLA2 is present in the peritoneal environment 
and is secreted by the endometrial gland (30).
 The present study examined the association 
between the 763C>G sPLA2IIa gene polymor-
phism in patients with endometriosis and in 
control subjects in Iran. We observed that the 
genotype distribution for this polymorphism 
was significantly different between the indi-
viduals with and without endometriosis. In a 
previous study, a strong relationship was ob-
served between PLA2G2A polymorphism with 
serum sPLA2IIa levels (p<0.0001) (18). More-
over, by haplotype analysis, they reported that 
of the potential 64 haplotypes defined by SNPs 
of PLA2G2A, only six haplotypes occurred at a 
frequency >5% and these haplotypes were as-
sociated with sPLA2IIa levels (18).
Secretory PLA2IIa can modify LDL particles 
and it has been shown that these modified LDLs 
have enhanced affinity for proteoglycan and 
glycosaminoglycan binding (31-33). The inter-
action between LDL and proteoglycans, which 
induces LDL aggregation and fusion, is a factor 
that contributes to the pathogenesis. Moreover, 
the macrophage-specific over-expression of 
group IIa sPLA2 increases atherosclerosis and 
enhances collagen deposition (34, 35). Ploak et 
al. showed an increased level of oxLDL in the 
peritoneal fluid of women with endometriosis 
in advanced stages (36).
 The data from our experimental study dem-
onstrate that women with endometriosis have 
dyslipidemia compared with the control sub-
jects. These findings are consistent with previ-
ous studies (11).
A study on Caucasian men and women with 
Type II diabetes mellitus (T2D) reported that 
the frequency of the minor allele at this poly-
morphism was 23%, 95%CI=0.20-0.25), which 
is similar to the frequency observed in the con-
trol group of our study (18). Furthermore, con-
sistent with Wooton et al, which reported no ef-
fect of the 763C>G polymorphism on HDL-C 
and TG levels in the Caucasian population with 
T2D (18), we found no association between this 
polymorphism and both HDL-C and TG levels 
in the present study. Our results showed no sig-
nificant difference in HDL-C levels in individu-
als with genotype GG compared with those with 
CC genotype. As, HDL-C levels depend on dif-
ferent factors including diet, exercise, environ-
ment and genetics, probably, the G allele is not 
the sole determinant of serum HDL-C levels. 
Overall, we observed a significant association 
between PLA2G2A and endometriosis risk.
Our research has shown that the risk of endo-
metriosis is lower in subjects with the G allele 
than individuals homozygous for the normal al-
lele. Moreover, our findings suggest that in GG 
homozygote women, total cholesterol and LDL-
C levels are less than those with CC genotype. 
Cholesterol and LDL-C, which are known in-
flammatory risk factors, may be involved in the 
occurrence and severity of disease, which may 
indicate beneficial effects of mutation in this 
gene. The 763C>G polymorphism of PLA2G2A 
is also in linkage disequilibrium with an identi-
fied functional polymorphism in this gene that 
may influence the risk of endometriosis. 
The main limitations of the present study 
were the relatively small sample size and the 
absence of data on sd-LDL and oxLDL parti-
cles. Another limitation of the present study 
was no standardization of the intensity of the 
physical activity of patients, a factor that may 
also influence the levels of serum lipids. Also, 
lack of data on sPLA2IIa activity was another 
limitation of this study. 
Conclusion
This study reports for the first time a sig-
nificant association between PLA2G2A gene 
polymorphism with the risk of endometriosis. 
443
The Secretory PLA2IIa Gene Polymorphism and Endometriosis
Despite the 763C>G polymorphism showing a 
tendency to decrease endometriosis risk, larger 
series are warranted to confirm this observation 
and to further study the association between 
PLA2G2A and endometriosis development.   
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